The majority of metastatic colorectal cancers (mCRC) are mismatch repair (MMR) proficient and unresponsive to immunotherapy, while MMR-deficient (MMRd) tumors often respond to immune-checkpoint-blockade. We previously reported that treatment of CRC preclinical models with temozolomide (TMZ) leads to MMR-deficiency, increased tumor mutational burden (TMB) and sensitization to immunotherapy. To clinically translate these findings, we designed the ARETHUSA clinical trial whereby O6-Methylguanine-DNA-methyltransferase (MGMT) deficient, MMR-proficient, RAS mutant mCRC patients received priming therapy with TMZ. Analysis of tissue biopsies and circulating tumor DNA (ctDNA) revealed the emergence of a distinct mutational signature and increased TMB after TMZ treatment. Multiple alterations in the nucleotide context favored by the TMZ signature emerged in MMR genes and the p.T1219I MSH6 variant was detected in ctDNA and tissue of 94% (16/17) of the cases. A patient's subset whose tumors displayed the MSH6 mutation, the TMZ mutational signature and increased TMB, achieved disease stabilization upon pembrolizumab treatment.

Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients

Crisafulli, Giovanni
First
;
Macagno, Marco;Barault, Ludovic;Luraghi, Paolo;Battuello, Paolo;Vitiello, Pietro Paolo;Germano, Giovanni;Di Nicolantonio, Federica
Co-last
;
Bardelli, Alberto
2022

Abstract

The majority of metastatic colorectal cancers (mCRC) are mismatch repair (MMR) proficient and unresponsive to immunotherapy, while MMR-deficient (MMRd) tumors often respond to immune-checkpoint-blockade. We previously reported that treatment of CRC preclinical models with temozolomide (TMZ) leads to MMR-deficiency, increased tumor mutational burden (TMB) and sensitization to immunotherapy. To clinically translate these findings, we designed the ARETHUSA clinical trial whereby O6-Methylguanine-DNA-methyltransferase (MGMT) deficient, MMR-proficient, RAS mutant mCRC patients received priming therapy with TMZ. Analysis of tissue biopsies and circulating tumor DNA (ctDNA) revealed the emergence of a distinct mutational signature and increased TMB after TMZ treatment. Multiple alterations in the nucleotide context favored by the TMZ signature emerged in MMR genes and the p.T1219I MSH6 variant was detected in ctDNA and tissue of 94% (16/17) of the cases. A patient's subset whose tumors displayed the MSH6 mutation, the TMZ mutational signature and increased TMB, achieved disease stabilization upon pembrolizumab treatment.
12
7
1662
1681
https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-21-1434/696348/Temozolomide-treatment-alters-mismatch-repair-and
Colorectal Cancer, Mismatch Repair, Temozolomide, Mutational Signature, MSH6
Crisafulli, Giovanni; Sartore-Bianchi, Andrea; Lazzari, Luca; Pietrantonio, Filippo; Amatu, Alessio; Macagno, Marco; Barault, Ludovic; Cassingena, Andrea; Bartolini, Alice; Luraghi, Paolo; Mauri, Gianluca; Battuello, Paolo; Personeni, Nicola; Zampino, Maria Giulia; Pessei, Valeria; Vitiello, Pietro Paolo; Tosi, Federica; Idotta, Laura; Morano, Federica; Valtorta, Emanuele; Bonoldi, Emanuela; Germano, Giovanni; Di Nicolantonio, Federica; Marsoni, Silvia; Siena, Salvatore; Bardelli, Alberto
File in questo prodotto:
File Dimensione Formato  
Crisafulli_CancerDiscov_2022_onlinepublication.pdf

Accesso aperto

Descrizione: Articolo Principale
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 4.78 MB
Formato Adobe PDF
4.78 MB Adobe PDF Visualizza/Apri
cd-21-1434-ssf1-sf7.pdf

Accesso aperto

Descrizione: Supplementary Data
Tipo di file: DATASET
Dimensione 1.79 MB
Formato Adobe PDF
1.79 MB Adobe PDF Visualizza/Apri
Crisafulli_275574_1_merged_1649949534.pdf

Accesso aperto

Descrizione: Crisafulli_accepted_postprint_with_supplementary
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 6.95 MB
Formato Adobe PDF
6.95 MB Adobe PDF Visualizza/Apri
1656.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 6.73 MB
Formato Adobe PDF
6.73 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1864543
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact